Molecular defects in T- and B-cell primary immunodeficiency diseases

Nature Reviews Immunology

Volumn 5, Issue 11, 2005, Pages 880-892

  Cunningham Rundles, Charlotte ^a   Ponda, Prashant P ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOGLOBULIN; MACROGOL; RETROVIRUS VECTOR; SULFAMETHOXAZOLE; TACROLIMUS; TRIMETHOPRIM;

AGAMMAGLOBULINEMIA; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CELLULAR IMMUNITY; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; COMMON VARIABLE IMMUNODEFICIENCY; ENZYME REPLACEMENT; GENETIC DISORDER; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERIMMUNOGLOBULINEMIA M; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNODYSREGULATION POLYENDOCRINOPATHY AND ENTEROPATHY X LINKED SYNDROME; IMMUNOGLOBULIN A DEFICIENCY; LUNG INFECTION; LYMPHOPROLIFERATIVE DISEASE; PRIMARY IMMUNE RESPONSE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRAL GENE THERAPY;

B-LYMPHOCYTES; BONE MARROW TRANSPLANTATION; FEMALE; GENE THERAPY; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; MALE; SEVERE COMBINED IMMUNODEFICIENCY; STEM CELL TRANSPLANTATION; T-LYMPHOCYTES;

EID: 27744447066     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1713     Document Type: Review

References (117)

1. Notarangelo, L. et al. Primary immunodeficiency diseases: an update. J. Allergy Clin. Immunol. 114, 677-687 (2004). This is an updated summary and classification scheme of primary immunodeficiency diseases that is based on the most recent consensus of the Primary Immunodeficiency Disease Classification Committee of the International Union of Immunological Societies.
2. + severe combined immunodeficiency. Nature Genet. 20, 394-397 (1998).
3. Dadi, H. K., Simon, A. J. & Roifman, C. M. Effect of CD36 deficiency on maturation of α/β and γ/δ T-cell lineages in severe combined immunodeficiency. N. Engl. J. Med. 349, 1821-1828 (2003).
4. de Saint Basile, G. et al. Severe combined immunodeficiency caused by deficiency in either the δ or the ε subunit of CD3. J. Clin. Invest. 114, 1512-1517 (2004).
5. Noguchi, M. et al. Interleukin-2 receptor γ chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73, 147-157 (1993).
6. Kung, C. et al. Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease. Nature Med. 6, 343-345 (2000).
7. Russell, S. M. et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 270, 797-800 (1995).
8. Moshous, D. et al. Artemis, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency. Cell 105, 177-186 (2001).
9. Schwarz, K. et al. RAG mutations in human B cell-negative SCID. Science 274, 97-99 (1996).
10. Giblett, E., Anderson, J., Cohen, F., Pollara, B. & Meuwissen, H. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2, 1067-1069 (1972).
11. Buckley, R. H. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu. Rev. Immunol. 22, 625-655 (2004). This paper reviews SCID and the outcomes of bone-marrow transplantation of 132 patients over two decades.
12. Patel, D. D. et al. Thymic function after hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N. Engl. J. Med. 342, 1325-1332 (2000).
13. Myers, L. A., Patel, D. D., Puck, J. M. & Buckley, R. H. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood 99, 872-878 (2002).
14. Lindegren, M. L. et al. Applying public health strategies to primary immunodeficiency diseases: a potential approach to genetic disorders. MMWR Recomm. Rep. 53, 1-29 (2004).
15. Chan, K. & Puck, J. M. Development of population-based newborn screening for severe combined immunodeficiency. J. Allergy Clin. Immunol. 115, 391-398 (2005). This paper describes the novel approach of measuring the number of TRECs in DNA isolated from dried blood spots to screen infants for SCID.
16. Yagi, H. et al. Role of TBX1 in human del22q11.2 syndrome. Lancet 362, 1366-1373 (2003).
17. Stoller, J. Z. & Epstein, J. A. Identification of a novel nuclear localization signal in Tbx1 that is deleted in DiGeorge syndrome patients harboring the 1223delC mutation. Hum. Mol. Genet. 14, 885-892 (2005).
18. Arnaiz-Villena, A. et al. Primary immunodeficiency caused by mutations in the gene encoding the CD3-γ subunit of the T-lymphocyte receptor. N. Engl. J. Med. 327, 529-533 (1992).
19. Soudais, C., de Villartay, J.-P., Le Deist, F., Fischer, A. & Lisowska-Grospierre, B. Independent mutations of the human CD3-ε gene resulting in a T cell receptor/CD3 complex immunodeficiency. Nature Genet. 3, 77-81 (1993).
20. de la Salle, H. et al. HLA class I deficiencies due to mutations in subunit 1 of the peptide transporter TAP1. J. Clin. Invest. 103, R9-R13 (1999).
21. Donato, L. et al. Association of HLA class I antigen deficiency related to a TAP2 gene mutation with familial bronchiectasis. J. Pediatr. 127, 895-900 (1995).
22. Masternak, K., Muhlethaler-Mottet, A., Villard, J., Peretti, M. & Reith, W. Molecular genetics of the bare lymphocyte syndrome. Rev. Immunogenet. 2, 267-282 (2000).
23. lck in an infant with severe combined immunodeficiency. J. Clin. Invest. 102, 421-429 (1998).
24. + thymic selection in humans lacking Zap-70 kinase. Cell 76, 947-958 (1994).
25. de la Galle-Martin, O. et al. Familial CD8 deficiency due to a mutation in the CD8α gene. J. Clin. Invest. 108, 117-123 (2001).
26. Engel, P., Eck, M. J. & Terhorst, C. The SAP and SLAM families in immune responses and X-linked lymphoproliterative disease. Nature Rev. Immunol. 3, 813-821 (2003).
27. Ochs, H. D., Ziegler, S. F. & Torgerson, T. R. FOXP3 acts as a rheostat of the immune response. Immunol. Rev. 203, 156-164 (2005).
28. Gambineri, E., Torgerson, T. R. & Ochs, H. D. Immune dysregulation, polyendocrinopathy enteropathy and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr. Opin. Rheumatol. 15, 430-435 (2003).
29. Bennett, C. L. et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nature Genet. 27, 20-21 (2001).
30. high regulatory cells in human peripheral blood. J. Immunol. 167, 1245-1253 (2001).
31. Kobayashi, I., Nakanishi, M., Okano, M., Sakiyama, Y. & Matsumoto, S. Combination therapy with tacrolimus and betamethasone for a patient with X-linked auto-immune enteropathy. Eur. J. Pediatr. 154, 594-595 (1995).
32. Baud, O. et al. Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation. N. Engl. J. Med. 344, 1758-1762 (2001).
33. Wildin, R. S., Smyk-Pearson, S. & Filipovich, A. H. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. J. Med. Genet. 39, 537-545 (2002).
34. Aaltonen, J. et al. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nature Genet. 17, 399-403 (1997).
35. Su, M. A. & Anderson, M. S. Aire: an update. Curr. Opin. Immunol. 16, 746-752 (2004).
36. Gotter, J., Brors, B., Hergenhahn, M. & Kyewski, B. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J. Exp. Med. 199, 155-166 (2004). This study investigates the expression of self-proteins at the surface of human thymic epithelial cells, and the authors postulate a role for AIRE in regulating the expression of these self-proteins.
37. + T cell homeostatic expansion. Nature Immunol. 5, 426-434 (2004).
38. Uchida, D. et al. AIRE functions as an E3 ubiquitin ligase. J. Exp. Med. 199, 167-172 (2004).
39. Le Deist, F. et al. Clinical, immunological, and pathological consequences of Fas-deficient conditions. Lancet 348, 719-723 (1996).
40. Rieux-Laucat, F., Fischer, A. & Le Deist, F. L. Cell-death signaling and human disease. Curr. Opin. Immunol. 15, 325-331 (2003).
41. Rieux-Laucat, F. et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268, 1347-1349 (1995).
42. Vaishnaw, A. K. et al. The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations. J. Clin. Invest. 103, 355-363 (1999).
43. Chun, H. J. et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature 419, 395-399 (2002).
44. Wang, J., Chun, H. J., Wong, W., Spencer, D. M. & Lenardo, M. J. Caspase-10 is an initiator caspase in death receptor signaling. Proc. Natl Acad. Sci. USA 98, 13884-13888 (2001).
45. Wu, J. et al. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J. Clin. Invest. 98, 1107-1113 (1996).
46. Ramenghi, U. et al. Deficiency of the Fas apoptosis pathway without Fas gene mutations is a familial trait predisposing to development of autoimmune diseases and cancer. Blood 95, 3176-3182 (2000).
47. Holzelova, E. et al. Autoimmune lymphoproliterative syndrome with somatic Fas mutations. N. Engl. J. Med. 351, 1409-1418 (2004).
48. Kenter, A. L. Class-switch recombination: after the dawn of AID. Curr. Opin. Immunol. 15, 190-198 (2003).
49. Papavasiliou, F. N. & Schatz, D. G. Somatic hypermutation of immunoglobulin genes: merging mechanisms for genetic diversity. Cell 109, S35-S44 (2002).
50. Aruffo, A. et al. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 72, 291-300 (1993).
51. Revy, P. et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the hyper-IgM syndrome (HIGM2). Cell 102, 565-575 (2000).
52. Imai, K. et al. Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination. Nature Immunol. 4, 1023-1028 (2003).
53. Ferrari, S. et al. Mutations of CD40 gene cause an autosomal recessive form of immunodeficiency with hyper IgM. Proc. Natl Acad. Sci. USA 98, 12614-12619 (2001).
54. Kutukculer, N. et al. Disseminated Cryptosporidium infection in an infant with hyper-IgM syndrome caused by CD40 deficiency. J. Pediatr. 142, 194-196 (2003).
55. Imai, K. et al. Hyper-IgM syndrome type 4 with a B lymphocyte-intrinsic selective deficiency in Ig class-switch recombination. J. Clin. Invest. 112, 136-142 (2003).
56. Doffinger, R. et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-κB signaling. Nature Genet. 27, 277-285 (2001).
57. Jain, A. et al. Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia. Nature Immunol. 2, 223-228 (2001).
58. Orange, J. S. et al. The presentation and natural history of immunodeficiency caused by nuclear factor κB essential modulator mutation. J. Allergy Clin. Immunol. 113, 725-733 (2004).
59. Courtois, G. et al. A hypermorphic IκBα mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. J. Clin. Invest. 112, 1108-1115 (2003).
60. Minegishi, Y. et al. Mutations in activation-induced cytidine deaminase in patients with hyper IgM syndrome. Clin. Immunol. 97, 203-210 (2000).
61. Catalan, N. et al. The block in immunoglobulin class switch recombination caused by activation-induced cytidine deaminase deficiency occurs prior to the generation of DNA double strand breaks in switch μ region. J. Immunol. 171, 2504-2509 (2003).
62. Chaudhuri, J., Khuong, C. & Alt, F. W. Replication protein A interacts with AID to promote deamination of somatic hypermutation targets. Nature 430, 992-998 (2004).
63. Etzioni, A. & Ochs, H. D. The hyper IgM syndrome - an evolving story. Pediatr. Res. 56, 1-7 (2004).
64. Puel, A., Picard, C., Ku, C.-L., Smahi, A. & Casanova, J. L. Inherited disorders of NF-κB-mediated immunity in man. Curr. Opin. Immunol. 16, 34-41 (2004).
65. Ochs, H. D. & Notarangelo, L. X-linked immunodeficiencies. Curr. Allergy Asthma Rep. 4, 339-348 (2004).
66. Akira, S. & Takeda, K. Toll-like receptor signalling. Nature Rev. Immunol. 4, 499-511 (2004).
67. Medvedev, A. E. et al. Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J. Exp. Med. 198, 521-531 (2003).
68. Picard, C. et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299, 2076-2079 (2003). This report describes three children with a defect in TLR signalling and their susceptibility to infection.
69. Saleh, M. et al. Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature 429, 75-79 (2004). References 67-69 show the emerging role of defects in the innate immune system as an aetiology for primary immunodeficiency diseases.
70. Buckley, R. H. Primary immunodeficiency diseases due to defects in lymphocytes. N. Engl. J. Med. 343, 1313-1324 (2000).
71. Bruton, O. Agammaglobulinemia. Pediatrics 9, 722-728 (1952).
72. Vetrie, D. et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 361, 226-233 (1993).
73. Buckley, R. H. Pulmonary complications of primary immunodeficiencies. Paediatr. Respir. Rev. 5, S225-S233 (2004).
74. Curtin, J. J., Webster, A. D., Farrant, J. & Katz, D. Branchiectasis in hypogammaglobulinaemia - a computed tomography assessment. Clin. Radiol. 44, 82-84 (1991).
75. McKinney, R. E. Jr, Katz, S. L. & Wilfert, C. M. Chronic enteroviral meningoencephalitis in agammaglobulinemic patients. Rev. Infect. Dis. 9, 334-356 (1987).
76. Minegishi, Y. et al. Mutations in the human λ5/14.1 gene result in B cell deficiency and agammaglobulinemia. J. Exp. Med. 187, 71-77 (1998).
77. Minegishi, Y. et al. Mutations in Igα (CD79a) result in a complete block in B-cell development. J. Clin. Invest. 104, 1115-1121 (1999).
78. Yel, L. et al. Mutations in the μ heavy-chain gene in patients with agammaglobulinemia. N. Engl. J. Med. 335, 1486-1493 (1996).
79. Meffre, E. et al. Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development. J. Clin. Invest. 108, 879-886 (2001).
80. Aoki, Y., Isselbacher, K. & Pillai, S. Bruton tyrosine kinase is tyrosine phosphorylated and activated in pre-B lymphocytes and receptor-ligated B cells. Proc. Natl Acad. Sci USA 91, 10606-10609 (1994).
81. 2+ mobilization by X-linked agammaglobulinaemia (XLA) B cells in response to ligation of the B cell receptor (BCR). Clin. Exp. Immunol. 110, 386-391 (1997).
82. Ng, Y.-S., Wardemann, H., Chelnis, J., Cunningham-Rundles, C. & Meffre, E. Bruton's tyrosine kinase is essential for human B cell tolerance. J. Exp. Med. 200, 927-934 (2004).
83. Sawada, A. et al. A congenital mutation of the novel gene LRRC8 causes agammaglobulinemia in humans. J. Clin. Invest. 112, 1707-1713 (2003).
84. Primary Immunodeficiency Diseases. Report of an IUIS Scientific Committee. International Union of Immunological Societies. Clin. Exp. Immunol. 118, 1-28 (1999).
85. -) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease. Blood 99, 1544-1551 (2002).
86. Cunningham-Rundles, C. & Bodian, C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin. Immunol. 92, 34-48 (1999). This is the largest case study so far of patients with CVID.
87. Morra, M. et al. Alterations of the X-linked lymphoproliferative disease gene SH2D1A in common variable immunodeficiency syndrome. Blood 98, 1321-1325 (2001).
88. Grimbacher, B. et al. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nature Immunol. 4, 261-268 (2003).
89. Salzer, U. et al. ICOS deficiency in patients with common variable immunodeficiency. Clin. Immunol. 113, 234-240 (2004). References 88 and 89 report that a defect in ICOS is the cause of CVID in nine individuals.
90. Choe, J. & Choi, Y. S. IL-10 interrupts memory B cell expansion in the germinal center by inducing differentiation into plasma cells. Eur. J. Immunol. 28, 508-515 (1998).
91. Lee, W.-I. et al. Inducible CO-stimulator molecule, a candidate gene for defective isotype switching, is normal in patients with hyper-IgM syndrome of unknown molecular diagnosis. J. Allergy Clin. Immunol. 112, 958-964 (2003).
92. Gross, J. A. et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404, 995-999 (2000).
93. Thompson, J. S. et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293, 2108-2111 (2001).
94. Rennert, P. et al. A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member APRIL, inhibits tumor cell growth. J. Exp. Med. 192, 1677-1684 (2000).
95. Litinskiy, M. B. et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nature Immunol. 3, 822-829 (2002).
96. Cunningham-Rundles, C. Physiology of IgA and IgA deficiency. J. Clin. Immunol. 21, 303-309 (2001).
97. Burrows, P. D. & Cooper, M. D. IgA deficiency. Adv. Immunol. 65, 245-276 (1997).
98. Vorechovsky, I. et al. Family and linkage study of selective IgA deficiency and common variable immunodeficiency. Clin. Immunol. Immunopathol. 77, 185-192 (1995).
99. Vorechovsky, I., Webster, A. D. B., Plebani, A. & Hammarstrom, L. Genetic linkage of IgA deficiency to the major histocompatibility complex: evidence for allele segregation distortion, parent-of-origin penetrance differences, and the role of anti-IgA antibodies in disease predisposition. Am. J. Hum. Genet. 64, 1096-1109 (1999).
100. Kralovicova, J., Hammarstrom, L., Plebani, A., Webster, A. D. B. & Vorechovsky, I. Fine-scale mapping at IGAD1 and genome-wide genetic linkage analysis implicate HLA-DQ/DR as a major susceptibility locus in selective IgA deficiency and common variable immunodeficiency. J. Immunol. 170, 2765-2775 (2003).
101. Hershfield, M. S. PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. Clin. Immunol. Immunopathol. 76, S228-S232 (1995).
102. Buckley, R. H. A historical review of bone marrow transplantation for immunodeficiencies. J. Allergy Clin. Immunol. 113, 793-800 (2004).
103. Antoine, C. et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet 361, 553-560 (2003). This paper details the outcomes of 475 patients in Europe who, over three decades, received a haematopoietic stem-cell transplant.
104. Buckley, R. H. et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N. Engl. J. Med. 340, 508-516 (1999).
105. Sarzotti, M. et al. T cell repertoire development in humans with SCID after nonablative allogeneic marrow transplantation. J. Immunol. 170, 2711-2718 (2003).
106. Cavazzana-Calvo, M. et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669-672 (2000). This report was the first description of successful gene therapy for patients with X-linked SCID.
107. Hacein-Bey-Abina, S. et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 346, 1185-1193 (2002).
108. Aiuti, A. et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296, 2410-2413 (2002).
109. Hacein-Bey-Abina, S. et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415-419 (2003).
110. McCormack, M. P. & Rabbitts, T. H. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 350, 913-922 (2004). This study details the role of LMO2 in the development of the insertional mutagenesis that was seen in several patients with X-linked SCID after gene therapy.
111. + progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant. 27, 777-783 (2001).
112. Kohn, D. B. et al. American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol. Ther. 8, 180-187 (2003).
113. Frank, J. et al. Exposing the human nude phenotype. Nature 398, 473-474 (1999).
114. Fu, C., Turck, C. W., Kurosaki, T. & Chan, A. C. BLNK: a central linker protein in B cell activation. Immunity 9, 93-103 (1998).
115. Minegishi, Y. et al. An essential role for BLNK in human B cell development. Science 286, 1954-1957 (1999).
116. Salzer, U. et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nature Genet. 37, 820-828 (2005).
117. Castigli, E. et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nature Genet. 37, 829-834 (2005).